Drug Pipeline Database & Screener

Over 1500 drug entries from over 400 biotech companies in Phase 2, 3 or NDA development.

Company SCREENER also available to filter through financial and clinical data. Financial filters include market cap, short ratio, price to book and relative volume, while you can also run a filter according to the development stage of the drug (e.g. Phase 2, PDUFA date).

N.B. The short ratio is the number of shares sold short divided by the average daily volume, also known as the number of "days to cover".

Drug pipeline data are updated at the end of each trading day. Click on the date for the source of the catalyst. 


Visit the FDA Calendar for  latest Biotech Stock Catalyst dates (PDUFA dates and clinical data readouts).

Alternatively, the BioPharmCatalyst Biotech Stocks page provides data on daily price and volume movers and information on individual companies.


Subscribe HERE to ensure you receive your weekly free copy of the BioPharmCatalyst Biotech Watchlist and/or our daily option of Biotech Price Movers and Pipeline Database updates. 

Financial data are delayed 15-35 minutes.


Showing 467 companies
Screener
Sort
Stage
Market Cap
Price
Short ratio
Relative Volume
Price to book
FDA Calendar
Company
Price
Change
Market Cap
Outstanding Shares
Short Ratio
Updated
$82.27
+0.28  0.34%
$3.6 billion
44.2 million
0.20
04/20/2017
Tap to view 5 drugs
Drug Indication Stage News
Annexin V-128 Early Breast Cancer Phase 2 Phase 2 initiated September 2016
Annexin V-128 Rheumatoid arthritis and ankylosing spondylitis Phase 1/2 Ongoing
Apoptosis Necrosis Phase 2 Phase 2 initiated September 2016
Somakit-TATE Neuroendocrine tumor diagnosis Approved Approved June 1, 2016.
Somakit-TOC Neuroendocrine cancers Positive opinion by EMA released in October 2016.
$106.49
+1.85  1.77%
$170 billion
1.6 billion
3.38
01/15/2018
Tap to view 30 drugs
Drug Indication Stage News
ABBV-8E12 Progressive supranuclear palsy (PSP) Phase 2 Phase 2 initiation announced January 25, 2017.
ABBV-8E12 Alzheimer's disease Phase 2 Phase 2 initiation announced January 25, 2017.
ABT-414 Recurrent glioblastoma (rGBM) Phase 1 Phase 1 data at ASCO. Oral Abstract 2003. June 4, 2017.
ABT-494 Psoriatic Arthritis Phase 3 Phase 3 trial to commenced 2017.
ABT-494 Crohn’s Disease Phase 2b Phase 2 positive data at DDW Meeting May 9, 2017. Phase 3 trial to be initiated later in 2017.
ABT-494 Atopic Dermatitis Phase 3 Phase 2b data released September 7, 2017 - primary endpoint met. Phase 3 trial to be initiated 1H 2018.
ABT-494 - SELECT-BEYOND Rheumatoid arthritis Phase 3 Phase 3 top-line released September 11, 2017. Endpoints met but with two patient deaths.
ABT-494 - SELECT-COMPARE Rheumatoid arthritis Phase 3 Phase 3 data due 2018.
ABT-494 - SELECT-MONOTHERAPY Rheumatoid arthritis Phase 3 Phase 3 data released December 20, 2017 - primary endpoint and key secondary endpoints met.
ABT-494 (upadacitinib) - SELECT-NEXT Rheumatoid arthritis Phase 3 Phase 3 top-line data released June 7, 2017 - primary endpoints met.
Glecaprevir/Pibrentasvir (G/P) Hepatitis C virus (HCV) Approved Approval announced August 3, 2017.
Ibrutinib Relapsed or refractory MCL mantle cell lymphoma Approved Approved November 13, 2013.
Imbruvica Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy Approved Approved February 12, 2014.
Imbruvica Deletion 17p Approved Approved July 19, 2014.
IMBRUVICA Waldenström’s Macroglobulinemia Approved Approved January 29, 2015 - PCYC
Imbruvica Second-line Chronic graft-versus-host disease (GVHD) Approved Approval announced August 2, 2017.
Imbruvica Marginal zone lymphoma Approved sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Imbruvica - PHOENIX First-line Diffuse large B-cell lymphoma (DLBCL) Phase 3 Phase 3 data possibly due 2018.
Risankizumab Ulcerative colitis Phase 3 Phase 3 trial to be initiated 1H 2018.
Risankizumab Crohn’s Disease Phase 3 Phase 3 trial to commence 2H 2017.
Risankizumab Psoriasis Phase 3 Phase 3 data released October 26, 2017 - primary endpoints met.
Risankizumab Psoriatic Arthritis Phase 2b Phase 3 trial planned for 2018.
Rova-T First-line small cell lung cancer (SCLC) maintenance Phase 3 Phase 3 trial to commence 2017.
Rova-T (TRINITY) Third-line Small Cell Lung Cancer Phase 2 Phase 2 pivotal data 2Q 2018.
Veliparib Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC) Phase 3 Phase 3 trial did not meet primary endpoints - April 19, 2017.
Venclexta First-line Diffuse large B-cell lymphoma (DLBCL) Phase 3 Phase 3 trial planned.
Venclexta Follicular lymphoma (FL) Phase 3 Phase 3 trial planned.
Venclexta (MURANO) Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) Phase 3 Phase 3 data released September 18, 2017 - PFS primary endpoint met. LBA at ASH data showed PFS of 85% after 24 months.
Venetoclax Relapsed or refractory multiple myeloma Phase 3 Phase 3 trial initiated July 2016. Data due 2019.
VIEKIRA PAK HCV - genotype 1 Approved Approved December 19, 2014.
$14.85
+0.25  1.71%
$694.6 million
46.8 million
10.23
01/15/2018
Tap to view 4 drugs
Drug Indication Stage News
ABO-101 Sanfilippo syndrome type B (MPS IIIB) Phase 1/2 Phase 1/2 commencement of enrollment announced December 20, 2017.
ABO-101 Recessive dystrophic epidermolysis bullosa (RDEB) Phase 2 Phase 2 enrollment commenced September 2016.
ABO-102 Sanfilippo syndrome type A (MPS IIIA) Phase 1/2 Phase 1/2 commencement of enrollment in pivotal trial expansion announced October 11, 2017.
EB-101 Recessive dystrophic epidermolysis bullosa (RDEB) Phase 1/2 Noted July 18, 2017 that Phase 3 trial will commence in early 2018.
$1.65
+0.05  3.13%
$19.4 million
11.8 million
1.86
01/09/2018
Tap to view 1 drug
Drug Indication Stage News
Gencaro - GENETIC-AF trial Chronic Heart Failure Phase 2b Phase 2b completion of enrollment announced August 16, 2017 - top-line data due March 2018.
$5.15
-0.05  -0.96%
$286.1 million
55.6 million
2.74
01/15/2018
Tap to view 4 drugs
Drug Indication Stage News
AB-423 (MAD) Hepatitis B (HBV) Phase 2 Phase 2 trial to be initiated 1Q 2018.
ARB-1467 Hepatitis B (HBV) Phase 2 Phase 2 Cohort 4 data released September 25, 2017 with detailed data due at AASLD in October 2017.
ARB-1467, tenofovir, and pegylated interferon Hepatitis B (HBV) Phase 2 Phase 2 interim data due 2H 2018 with full data due 2019.
TKM-PLK1 Hepatocellular carcinoma (HCC) Phase 1/2 Phase 1/2 data released July 2016. Intends to explore partnership opportunities to enable further study
$28.93
+2.01  7.47%
$3.6 billion
124.2 million
7.01
01/15/2018
Tap to view 6 drugs
Drug Indication Stage News
Pimavanserin Adjunctive treatment in patients with negative symptoms of schizophrenia Phase 2 Phase 2 initiated November 2016.
Pimavanserin Adjunctive treatment of schizophrenia Phase 3 Phase 3 initiated November 2016.
Pimavanserin Parkinson’s disease psychosis (PDP) Approved Approved April 29 2016
Pimavanserin - CLARITY Adjunctive Treatment in Patients With Major Depressive Disorder Phase 2 Phase 2 initiation announced December 1, 2016.
Pimavanserin - Harmony Alzheimer’s disease psychosis Phase 3 Phase 3 trial initiation announced October 4, 2017.
Pimavanserin - SERENE Alzheimer’s disease agitation Phase 2 Announced October 4, 2017 that trial will be discontinued.
$18.71
-0.39  -2.04%
$140.3 million
7.5 million
1.12
09/25/2017
Tap to view 2 drugs
Drug Indication Stage News
EDSIVO Vascular Ehlers-Danlos Syndrome Phase 3 NDA filing 1H 2018.
Tovaxin (Tcelna) Secondary Progressive MS (SPMS) Phase 2b Phase 2b trial did not meet primary endpoint - October 28, 2016.
$3.01
+0.02  0.67%
$415 million
137.9 million
1.56
01/15/2018
Tap to view 4 drugs
Drug Indication Stage News
ACH-4471 C3 glomerulopathy (C3G) Phase 2 Phase 2 interim data released November 14, 2017.
ACH-4471 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 2 Phase 2 initiation announced April 6, 2017. Interim data released August 8, 2017.
JNJ-4178 Hepatitis C (HCV) Phase 2a Janssen noted September 11, 2017 that no further development planned.
JNJ-4178 - OMEGA-1 Hepatitis C (HCV) Phase 2b Janssen noted September 11, 2017 that no further development planned.
$1.51
+0.03  1.97%
$18 million
11.9 million
1.17
11/10/2017
Tap to view 1 drug
Drug Indication Stage News
Cytisine Smoking cessation Phase 3 Phase 3 trial to be initiated mid-2018.
$13.51
+0.37  2.82%
$769 million
56.9 million
13.79
01/15/2018
Tap to view 4 drugs
Drug Indication Stage News
ACI-24 (anti-Abeta vaccine) Alzheimer's disease-like characteristics in individuals with Down syndrome Phase 1/2 Phase 1/2 completion of recruitment of low-dose cohort noted September 12, 2017. Interim data due 2018.
Crenezumab - CREAD 1 Alzheimer’s disease Phase 3 Phase 3 trial commennced 1Q 2016. Phase 2 trial did not meet co-primary endpoints. IPO September 23, 2016. Data due 2020.
Crenezumab - CREAD 2 Alzheimer’s disease Phase 3 Second Phase 3 trial initiation announced February 28, 2017.
RO7105705 Alzheimer’s disease Phase 1b Phase 2 commencement of dosing announced November 2, 2017.
$24.79
+0.39  1.60%
$764.4 million
30.8 million
6.41
01/15/2018
Tap to view 7 drugs
Drug Indication Stage News
A-101 Common warts (verruca vulgaris) Phase 2 Phase 2 data released January 8, 2018 - endpoints met. Phase 3 trial to be initiated 2H 2018.
ATI-50001 Alopecia areata Phase 2 Phase 2 trial to be initiated 1H 2018.
ATI-50002 Vitiligo Phase 2 Phase 2 open label trial initiation announced December 19, 2017.
ATI-50002 - dose ranging Alopecia areata Phase 2 Phase 2 data due year-end 2018.
ATI-50002 - open label Alopecia areata Phase 2 Phase 2 data due 1H 2018.
ATI-50002 - PK/safety Alopecia areata Phase 2 Phase 2 data due 1H 2018.
ESKATA (hydrogen peroxide) Seborrheic keratosis (SK) Approved Approval announced December 15, 2017.
$2.00
-0.05  -2.44%
$100.7 million
50.3 million
9.89
11/10/2017
Tap to view 3 drugs
Drug Indication Stage News
ARX-04 (SAP302) Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury Phase 3 Phase 3 data released August 15 2016
DSUVIA (ARX-04) Moderate-to-severe acute pain following a surgical procedure CRL CRL issued October 12, 2017.
Zalviso Post-operative pain following open abdominal surgery and hip or knee replacement surgery Phase 3 CRL Jul 26 2014. Additional clinical trial required. Data released August 1, 2017. NDA resubmission due YE 2017.
$1.13
+0.11  10.78%
$28.1 million
24.8 million
0.03
11/14/2017
Tap to view 1 drug
Drug Indication Stage News
CaPre Hypertriglyceridemia Phase 3 Phase 3 to begin treatment early 2018.
$8.50
+0.41  5.07%
$796.3 million
93.7 million
5.29
01/15/2018
Tap to view 5 drugs
Drug Indication Stage News
NY-ESO T-cell therapy Synovial sarcoma - cancer Phase 1/2 Oral presentation at CTOS November 9, 2017.
NY-ESO T-cell therapy Ovarian cancer Phase 1/2 Reported no clinical responses October 2016. Intends to alter dosage to include fludarabine.
NY-ESO T-cell therapy Myxoid round cell liposarcoma (MRCLS) Phase 1/2 Poster at CTOS November 9, 2017.
NY-ESO T-cell therapy Myeloma Phase 1/2 Updated data at ASH December 2017 - Overall response rate (ORR) at 100 days and one year were 76% and 44%.
NY-ESO T-cell therapy Non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1/2 initiated November 2015. Data are due 2017.
$1.46
+0.00  0.00%
$5.7 million
3.9 million
0.33
02/22/2017
Tap to view 3 drugs
Drug Indication Stage News
MDX (Metadoxine Extended Release (MG01CI)) Adult ADHD Phase 3 Phase 3 data released January 17, 2017 - failed to meet primary endpoint.
MDX (Metadoxine Extended Release (MG01CI)) Pediatric ADHD Phase 2 Phase 2b data released March 2015. Secondary cognitive measures did not produce statistically significant results.
MDX (Metadoxine Extended Release (MG01CI)) Fragile X Syndrome Phase 2 Phase 2 trial did not meet endpoints - June 2015.
$3.58
+0.04  1.13%
$162.2 million
45.3 million
1.11
06/27/2017
Tap to view 1 drug
$4.15
-0.20  -4.60%
$138.6 million
33.4 million
3.40
10/10/2017
Tap to view 2 drugs
Drug Indication Stage News
APC-1000 Asthma/COPD Phase 2 Phase 3 planned.
Epinephrine Pre-filled Syringe (PFS) Emergency treatment of anaphylaxis. Approved CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.
$40.79
+2.60  6.81%
$929.2 million
22.8 million
7.36
09/07/2017
Tap to view 4 drugs
Drug Indication Stage News
ADS-4101 Partial onset seizures in patents with epilepsy Phase 1b Phase 1b top-line data released September 7, 2017.
ADS-5102 Multiple sclerosis (MS) Phase 2 Phase 2 data released early June 2016. Evaluating Phase 3 pathway.
ADS-5102 Levodopa-Induced Dyskinesia Approved Approval announced August 24, 2017.
Namzaric Moderate to severe dementia of the Alzheimer's type. Approved Approved December, 24 2014.
$7.55
+0.25  3.42%
$583.6 million
77.3 million
11.34
01/15/2018
Tap to view 5 drugs
Drug Indication Stage News
ADU-S100 Solid tumors or lymphomas Phase 1b Phase 1b initiation of dosing announced September 26, 2017.
BION-1301 Multiple Myeloma Phase 1/2 Phase 1/2 initiation announced December 18, 2017.
CRS-207 and GVAX Pancreas - ECLIPSE trial Pancreatic cancer Phase 2b Phase 2b primary endpoint not met - May 2016
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial Pancreatic cancer Phase 2b Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
CRS-207 with pembrolizumab Mesothelioma - cancer Phase 2 Noted December 12, 2017 that development to be discontinued.
$5.15
+0.25  5.10%
$232 million
45 million
0.81
12/28/2017
Tap to view 2 drugs
$3.01
+0.08  2.73%
$124.3 million
41.3 million
8.50
01/15/2018
Tap to view 7 drugs
$2.40
+0.12  5.26%
$39.5 million
16.4 million
1.18
12/21/2017
Tap to view 2 drugs
Drug Indication Stage News
Macimorelin Acetate - Macrilen Adult Growth Deficiency Approved CRL issued November 2014. Approval announced following resubmission December 20, 2017.
Zoptrex Endometrial cancer Phase 3 Phase 3 trial did not meet primary endpoint - May 1, 2017.
$1.40
+0.10  7.69%
$62.5 million
44.7 million
0.69
01/15/2018
Tap to view 2 drugs
Drug Indication Stage News
AFM13 Hodgkin Lymphoma - Cancer Phase 2 Phase 2a full data due 2019.
AFM13 with Keytruda Hodgkin Lymphoma - Cancer Phase 1b Phase 1b poster at ASH December 9, 2017.ORR 83% (5/6).
$4.08
+0.11  2.77%
$408.7 million
100.2 million
10.91
01/22/2018
Tap to view 6 drugs
Drug Indication Stage News
AGEN1884 (anti-CTLA-4) Solid cancers Phase 1 Complete dose-escalation and define optimal combination dose 4Q 2017. BLA filing 2H 2019.
AGEN2034 (anti-PD-1) Solid tumors Phase 1 Phase 1 trial to complete dose-escalation and generate safety and pharmacodynamic data 4Q 2017. BLA filing 2H 2019.
AGEN2034 and AGEN1884 Solid tumors Phase 1/2 Phase 1/2 enrollment has been completed - noted January 22, 2018.
INCAGN1876 Solid tumors - cancer Phase 1/2 Phase 1/2 trial commenced June 2016
INCAGN1949 Solid tumors - cancer Phase 1/2 Phase 1/2 trial initiation announced November 30, 2016.
Shingrix Shingles Approved Approval announced October 20, 2017.
$78.35
+8.46  12.10%
$3.8 billion
48.8 million
18.92
01/15/2018
Tap to view 6 drugs
Drug Indication Stage News
AG-120 IDH1 mutant positive cholangiocarcinoma - cancer Phase 3 Phase 3 initiated December 2016.
AG-120 and VIDAZA - AGILE Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer Phase 3 Phase 3 initiated 2Q 2017.
AG-348 Pyruvate kinase deficiency Phase 2 Phase 2 first data released at EHA meeting June 2016. Updated data released at ASH December 10, 2017. Pivotal trials to be initiated 1H 2018.
Enasidenib (AG-221) - IDHENTIFY Refractory Acute myeloid leukemia (AML) - cancer Phase 3 Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of October 2017.
IDHIFA (enasidenib) - AG-221 Advanced hematologic malignancies with an IDH2 mutation Approved Approval announced August 1, 2017.
Ivosidenib IDH1m Relapsed/Refractory AML - cancer NDA Filing NDA filing announced December 26, 2017.
$7.40
+0.65  9.63%
$123.2 million
16.6 million
0.39
01/15/2018
Tap to view 3 drugs
Drug Indication Stage News
AEB1102 Acute myeloid leukemia (AML) or Myelodysplastic syndromes (MDS) Phase 1 Phase 1 initiation announced July 2016. Enrollment to be completed in 2017.
AEB1102 Arginase I deficiency Phase 1/2 Phase 1/2 top-line data due 3Q 2018.
AEB1102 + KEYTRUDA Small cell lung cancer (SCLC) Phase 1/2 Phase 1/2 trial to be initiated 1Q 2018.
$188.15
+6.82  3.76%
$62.6 billion
332.6 million
3.48
01/15/2018
Tap to view 22 drugs
Drug Indication Stage News
ABICIPAR Diabetic macular edema (DME) Phase 3 Phase 3 trial to be initiated 2018.
ABICIPAR Age-related macular degeneration (AMD) Phase 3 Phase 3 data due 2H 2018.
ABP 980 Herceptin biosimilar BLA Filing BLA filing announced July 31, 2017.
ATOGEPANT Prophylaxis (migraine) Phase 2b Phase 2b top-line data due 1H 2018.
AVYCAZ (ceftazidime and avibactam) Complicated Urinary Tract Infections (cUTI) Approved sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017.
Bimatoprost Androgenic Alopecia Phase 3 Phase 3 enrollment to be completed 2H 2018.
Botox Forehead lines Approved Approval (third indication) announced October 3, 2017.
Botox Depression Phase 2 Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned.
Brazikumab Crohn's disease Phase 2b Phase 2b data due 2018.
Brimo DDS Atrophic Age-related macular degeneration (AMD) Phase 2 Phase 2 top-line data due 1H 2018.
Cariprazine Bipolar I depression Phase 3 Phase 3 data released December 18, 2017 - primary endpoint met.
Cariprazine Maintenance Treatment of Schizophrenia Approved Approval announced November 13, 2017.
Cenicriviroc (CVC) Nonalcoholic steatohepatitis (NASH) Phase 3 Phase 3 trial has been initiated.
ESMYA (ulipristal acetate) Uterine Fibroids PDUFA Phase 3 data released January 18, 2017 - endpoints met. PDUFA date 1H 2018 - exact date not provided.
JUVÉDERM VOLLURE Correction of moderate to severe facial wrinkles and folds Approved Approval announced March 20, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults Chronic idiopathic constipation (CIC) Approved sNDA approval announced January 26, 2017.
MVASITM (bevacizumab-awwb) Biosimilar candidate to Avastin (bevacizumab) Approved Approved September 14, 2017.
Oxymetazoline HCl cream 1.0% Facial Erythema (Redness) Associated with Rosacea Approved Approved January 19, 2017.
RAPASTINEL Major depressive disorder (MDD) Phase 3 Phase 3 initiated October 2016. Data due 2019.
RELAMORELIN Diabetic Gastroparesis Phase 3 Phase 3 initiated 2H 2017 with top-line data due 2020.
RORγt agonist Psoriasis Phase 2b Phase 2b trial to be initiated 2H 2017.
UBROGEPANT Acute (migraine) Phase 3 Phase 3 initiated July 2016. Data due 1H 2018.
$3.50
-0.04  -1.13%
$119.7 million
34.2 million
0.57
12/22/2017
Tap to view 1 drug
Drug Indication Stage News
Twirla Contraceptive patch CRL CRL issued 2013. Further CRL issued December 22, 2017.
$4.15
+0.05  1.22%
$75.1 million
18.1 million
2.08
01/15/2018
Tap to view 2 drugs
Drug Indication Stage News
AAV Gene Therapy CNGB3 Achromatopsia Phase 1/2 Phase 1/2 continues to enroll - September 2017.
rAAV-hRS1 X-linked retinoschisis (XLRS) Phase 1/2 Phase 1/2 completion of enrollment due 1Q 2018 with data due after the last patient has been followed for six months (est 3Q 2018).
$38.26
-0.64  -1.65%
$2 billion
51.2 million
6.13
01/12/2018
Tap to view 3 drugs
$11.54
+0.00  0.00%
$489.2 million
42.4 million
9.57
01/11/2018
Tap to view 3 drugs
Drug Indication Stage News
C-Scape Complicated urinary tract infections (cUTI) due to multi-drug resistant (MDR) pathogens Phase 3 Phase 3 trial to be initiated 2018.
Plazomicin Complicated urinary tract infections (cUTI) PDUFA priority review Phase 3 data released December 12, 2016 - primary endpoint met. PDUFA date under priority review June 25, 2018.
Plazomicin - CARE Serious bacterial infections due to carbapenem-resistant Enterobacteriaceae (CRE) Phase 3 Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.
$15.22
+0.51  3.47%
$719.4 million
47.3 million
9.13
01/15/2018
Tap to view 4 drugs
Drug Indication Stage News
Vadadustat - FO2RWARD Renal anemia Phase 2 Phase 2 data due by the end of 2018.
Vadadustat - INNO2VATE Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD) Phase 3 Phase 3 initiated August 2016. Data due 2019.
Vadadustat - PRO2TECT Non-dialysis patients with anemia related to CKD (NDD-CKD) Phase 3 Phase 3 initiated January 2016. Phase 3 data due 2019.
Vadadustat - TRILO2GY Three-times-weekly dosing regimen for vadadustat Phase 3 Phase 3 trial to be initiated late 2017 or early 2018 with data due by the end of 2018.
$18.53
+0.63  3.52%
$1.2 billion
66.5 million
9.45
01/15/2018
Tap to view 7 drugs
Drug Indication Stage News
AKCEA-ANGPTL3-LRx Rare hyperlipidemias Phase 2 Phase 2b initiation announced March 30, 2017. Data due 2018.
AKCEA-ANGPTL3-LRx Non-alcoholic fatty liver disease (NAFLD), Hypertriglyceridemia and Type 2 Diabetes Mellitus Phase 2 Phase 2 initiation announced December 14, 2017. Top-line data due 2019.
AKCEA-APO(a)-LRx Hyperlipoproteinemia(a) and established cardiovascular disease Phase 2b Phase 2b initiation announced March 30, 2017. Data due 2018.
AKCEA-APOCIII-LRx Hyperlipoproteinemia(a) and established cardiovascular disease Phase 2b Phase 2b trial initiation announced January 5, 2017. Top-line data due 2019.
Volanesorsen Partial lipodystrophy rapidly Phase 3 Phase 3 initiated November 2015
Volanesorsen Familial partial lipodystrophy (FPL) Phase 3 Phase 3 initiated November 2015
Volanesorsen - APPROACH Familial chylomicronemia syndrome (FCS) PDUFA PDUFA date August 30, 2017.
$35.39
+2.39  7.24%
$315 million
8.9 million
0.65
11/15/2017
Tap to view 1 drug
Drug Indication Stage News
A4250 Progressive familial intrahepatic cholestasis (PFIC) Phase 3 Phase 3 to be initiated by the spring of 2018.
$16.25
-0.55  -3.27%
$1.1 billion
67.8 million
7.69
01/09/2018
Tap to view 3 drugs
$1.16
-0.04  -3.33%
$80.2 million
69.1 million
7.21
02/26/2017
Tap to view 1 drug
Drug Indication Stage News
Iluvien Diabetic macular edema Approved CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
$9.43
-0.22  -2.28%
$194.9 million
20.7 million
1.21
01/17/2018
Tap to view 2 drugs
Drug Indication Stage News
ALLN-177 Enteric Hyperoxaluria Phase 3 First of two Phase 3 trials to be initiated 1Q 2018 with top-line data due 2H 2019.
ALLN-177 Primary hyperoxaluria Phase 2 Phase 2 trial to be initiated 1Q 2018 with interim data due 2H 2018.
$131.00
+6.17  4.94%
$13 billion
99.2 million
4.91
01/15/2018
Tap to view 10 drugs
Drug Indication Stage News
ALN-CC5 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 1/2 Phase 1/2 initial data presented at ASH 2016.
ALN-CC5 (cemdisiran) Atypical hemolytic-uremic syndrome (aHUS) Phase 1/2 Phase 2 trial initiation announced September 26, 2017 with initial data due 2018.
ALN-GO1 Primary Hyperoxaluria Type 1 (PH1) Phase 1/2 Phase 1/2 initiated March 2016. Initial data released September 2016.
ALN-HBV Chronic hepatitis B virus (HBV) Phase 1/2 Phase 1/2 trial initiated July 2016. Ongoing as of February 2017.
ALN-TTRsc02 ATTR amyloidosis Phase 1 Phase 3 trial to be initiated late 2018.
Fitusiran Hemophilia A and B Phase 2 Noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Announced December 15, 2017 that clinical hold has been released. Dosing to resume later December.
Fitusiran (ATLAS) Hemophilia Phase 3 Phase 3 program initiation announced July 7, 2017 with initial data due mid-late 2019. Noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Announced December 15, 2017 that clinical hold has been released.
Givosiran Acute hepatic porphyrias Phase 3 Phase 3 trial initation announced November 7, 2017 with interim analysis data available in mid-2018.
Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR NDA Filing Phase 3 top-line data released September 20, 2017 - all endpoints met. Completion of NDA submission announced December 12, 2017.
Revusiran ENDEAVOUR ATTR in patients with familial amyloidotic cardiomyopathy (FAC) Phase 3 Phase 3 trial discontinued October 2016.
$11.54
+0.66  6.07%
$160.2 million
13.9 million
1.64
07/31/2017
Tap to view 1 drug
Drug Indication Stage News
N91115 Cystic Fibrosis - one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein Phase 2 Phase 2 data released February 24, 2017 - primary endpoint not met.
$9.32
+0.11  1.19%
$137.2 million
14.7 million
1.75
11/10/2017
Tap to view 2 drugs
Drug Indication Stage News
ALRN-6924 Peripheral T-cell lymphoma (PTCL) Phase 2a Phase 2a interim data due 1H 2018.
ALRN-6924 Solid tumors - cancer Phase 1/2 Phase 1 initial data presented at ASCO 2017. Completion of enrollment January 2017.
$1.82
+0.00  0.00%
$28.5 million
15.7 million
1.96
11/19/2017
Tap to view 1 drug
Drug Indication Stage News
NasoVAX Flu vaccine Phase 1/2 Phase 2 initial data due 1Q 2018.
$123.67
+2.62  2.16%
$27.6 billion
223.4 million
2.74
01/15/2018
Tap to view 6 drugs
Drug Indication Stage News
ALXN1101 Molybdenum cofactor deficiency (MoCD) Type A Phase 2/3 Phase 2/3 enrolling.
ALXN1210 atypical Hemolytic Uremic Syndrome (aHUS) Phase 3 Phase 3 enrollment to be completed early 2018; Phase 3 trial in pediatric patients has also been initiated.
ALXN1210 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 1/2 Phase 3 data due 2Q 2018.
Eculizumab Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD) Phase 3 Phase 3 enrollment to be completed in 2017 with data due mid-2018.
Eculizumab Refractory generalized myasthenia gravis (gMG) Approved Approval announced October 23, 2017.
SBC-103 MPS IIIB Phase 1/2 Phase 1/2 ongoing. No additional studies planned.
$14.35
+0.50  3.61%
$507.6 million
35.4 million
12.38
09/16/2017
Tap to view 4 drugs
Drug Indication Stage News
Digoxin immune fab (DIF) Severe preeclampsia in pregnant women Phase 2/3 Phase 2/3 commencement of enrollment announced June 1, 2017.
Feraheme Adults with iron deficiency anemia (IDA) PDUFA PDUFA date February 2, 2018 for sNDA filing.
Makena - auto injector Reduce the risk of preterm birth in women with a singleton pregnancy PDUFA sNDA filing announced April 17, 2017. PDUFA date February 14, 2018. 10-month review despite initial expectations of a 6-month review.
Rekynda Hypoactive sexual desire disorder (HSDD) Phase 3 NDA filing due early 2018.
AMGN Amgen Inc.
$192.33
+3.05  1.61%
$139.6 billion
725.9 million
3.22
01/15/2018
Tap to view 17 drugs
Drug Indication Stage News
ABP 710 REMICADE biosimilar - rheumatoid arthritis Phase 3 Phase 3 enrolling.
ABP 798 RITUXAN biosimilar - non-Hodgkin lymphoma Phase 3 Phase 3 enrolling.
ABP 980 Herceptin biosimilar BLA Filing BLA filing announced July 31, 2017.
BLINCYTO Ph+ R/R ALL Approved PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.
Corlanor Chronic Heart Failure Approved Approved April 15, 2015.
Erenumab Migraine PDUFA Phase 3 trial met primary endpoint September 2016. PDUFA date May 17, 2018.
EVENITY (Romosozumab) Osteoporosis CRL CRL issued July 16, 2017.
KYPROLIS (ARROW) Multiple Myeloma Phase 3 Phase 3 trial initiated June 2015. Data due 2019.
KYPROLIS (ASPIRE) Relapsed Multiple Myeloma Phase 3 Phase 3 trial met primary endpoint. HR 79%.
KYPROLIS (ENDEAVOR) Relapsed Multiple Myeloma PDUFA Phase 3 trial met PFS endpoint - March 2015. Announced February 28, 2017 that interim analysis met secondary endpoint of overall survival (OS). PDUFA date for sNDA April 30, 2018.
MVASITM (bevacizumab-awwb) Biosimilar candidate to Avastin (bevacizumab) PDUFA Approved September 14, 2017.
Parsabiv Secondary hyperparathyroidism (SHPT) Approved Approved February 7, 2017.
Prolia (denosumab) Glucocorticoid-induced osteoporosis (GIOP) PDUFA PDUFA date for sBLA filing May 28, 2017.
Repatha Cardiovascular disease Approved Approval announced December 1, 2017.
Tezepelumab Asthma Phase 2b Phase 2b data released September 7, 2017 - primary endpoint met.
Vectibix (Panitumumab) Wild-Type RAS Metastatic Colorectal Cancer Approved sBLA approval announced June 29, 2017.
XGEVA Multiple Myeloma Approved sBLA approval announced January 5, 2017.
$19.37
+0.00  0.00%
$890.6 million
46 million
9.95
02/23/2017
Tap to view 3 drugs
Drug Indication Stage News
Albuterol DPI Asthma Phase 2b
Naloxone Intranasal Opioid overdose CRL CRL announced February 21, 2017.
Primatene Mist (epinephrine inhalation aerosol) Asthma CRL CRL issued December 27, 2016.
$4.04
+0.07  1.76%
$1.1 billion
270.9 million
3.71
12/19/2017
Tap to view 1 drug
$114.78
-0.14  -0.12%
$2.7 billion
23.5 million
3.70
01/15/2018
Tap to view 3 drugs
Drug Indication Stage News
ANB020 Moderate-to-severe adult atopic dermatitis Phase 2b Phase 2a positive data released October 10, 2017. Phase 2b trial to be initiated 1H 2018 with data due 2019.
ANB020 Severe adult eosinophilic asthma Phase 2a Phase 2a data due 2Q 2018.
ANB020 Severe adult peanut allergy Phase 2a Phase 2a data due 1Q 2018.
$59.36
+0.33  0.56%
$870.3 million
14.7 million
22.06
01/15/2018
Tap to view 2 drugs
Drug Indication Stage News
Cingal Osteoarthritis Phase 3 Phase 3 completion of enrollment announced October 25, 2017. Trial to be completed 1H 2018.
Monovisc Osteoarthritis Approved Approved Feb 2014
$1.42
+0.14  10.94%
$30.5 million
21.5 million
4.22
01/22/2018
Tap to view 4 drugs
Drug Indication Stage News
Blisibimod IgA nephropathy Phase 2 Phase 2 primary endpoint not met following interim analysis. Trial to continue. Top-line data released August 28, 2017.
Blisibimod Lupus Phase 3 Phase 3 trial did not meet endpoints - November 10, 2016.
Sollpura - RESULT Exocrine pancreatic insufficiency Phase 3 Passed second futility analysis January 22, 2018. Phase 3 data due end 1Q 2018.
Sollpura (liprotamase) Cystic fibrosis who suffer from exocrine pancreatic insufficiency Phase 3 Top-line data released December 27, 2016 - missed primary endpoint.
$1.07
+0.00  0.00%
$14.4 million
13.5 million
6.82
01/04/2018
Tap to view 1 drug
Drug Indication Stage News
AB-SA01 Life-threatening infections Phase 2 Phase 2 trial planned for 2H 2018.
$19.00
+0.10  0.53%
$956.3 million
50.3 million
5.87
01/17/2018
Tap to view 4 drugs
Drug Indication Stage News
APL-2 IV - FILLY Geographic atrophy (GA) Phase 3 Phase 3 trial to commence 2H 2018. Phase 2 18 month safety & efficacy data due 1H 2018.
APL-2 subcutaneous Complement-dependent Nephropathies (CDN) Phase 2 Phase 2 monotherapy data due 2H 2018.
APL-2 subcutaneous Auto-immune Hemolytic Anemia (AIHA) Phase 2 Phase 2 monotherapy data due 1H 2018.
APL-2 subcutaneous and eculizumab (Soliris) Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 1b Phase 1b Soliris weaning & monotherapy expansion 1H 2018.
$2.64
-0.01  -0.38%
$40.2 million
15.2 million
4.94
11/03/2017
Tap to view 2 drugs
Drug Indication Stage News
RayVa Secondary Raynaud's Phenomenon Phase 2b Phase 2b planned - seeking partnership.
Vitaros Erectile dysfunction PDUFA PDUFA date for NDA resubmission February 17, 2018.
$12.24
+0.49  4.17%
$287.2 million
23.5 million
2.19
01/15/2018
Tap to view 4 drugs
Drug Indication Stage News
AQX-1125 Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Phase 2 Phase 2 planned for 1Q 2018.
AQX-1125 FLAGSHIP Chronic obstructive pulmonary disease (COPD) Phase 2 Phase 2 trail failed - July 2015
AQX-1125 KINSHIP Atopic dermatitis (AD) Phase 2 Phase 2 failed to demonstrate efficacy November 2015
AQX-1125 LEADERSHIP Bladder pain syndrome/interstitial cystitis (BPS/IC). Phase 3 Phase 2 trial did not meet endpoints - June 2015 but positive secondary endpoint data - August 2015. Phase 3 trial commenced September 2016. Data due 3Q 2018.
$2.42
+0.13  5.68%
$36.7 million
15.1 million
1.47
01/15/2018
Tap to view 2 drugs
$7.60
+0.30  4.11%
$361.3 million
47.5 million
5.97
01/15/2018
Tap to view 5 drugs
ARGX argenx SE
$66.25
-0.08  -0.12%
$2.1 billion
32 million
0.34
01/15/2018
Tap to view 5 drugs
Drug Indication Stage News
ARGX-110 Relapsed/refractory cutaneous T-cell lymphoma (CTCL) Phase 2 Phase 2 interim data ASH 2017 - of 22 patients 1 CR, 2 PRs, 10 with SD.
ARGX-110 Acute myeloid leukemia (AML) Phase 1/2 Phase 1/2 interim data at ASH 2017 - all six patients showed response including 3/6 with complete remission.
ARGX-113 Pemphigus vulgaris (PV) Phase 2 Phase 2 initiation announced September 26, 2017 with interim data due 2H 2018.
ARGX-113 Immune thrombocytopenia (ITP) Phase 2 Phase 2 data due 2H 2018.
ARGX-113 Myasthenia gravis (MG) Phase 2 Phase 2 data released December 11, 2017 - 75% of patients showed meaningful improvement.
$1.92
-0.07  -3.52%
$126.7 million
66 million
3.48
02/27/2017
Tap to view 2 drugs
Drug Indication Stage News
VIMOVO Gastric ulcers Approved Approved April 30, 2010.
YOSPRALA (PA32540/PA8140) Secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers Approved Approval announced September 15, 2016.
$35.89
+0.29  0.81%
$1.4 billion
39.3 million
4.40
01/15/2018
Tap to view 8 drugs
Drug Indication Stage News
APD371 Pain associated with Crohn's disease Phase 2 Phase 2 data due 1Q or 2Q 2018.
Etrasimod Primary biliary cholangitis (PBC) Phase 2 Phase 2 initiated 2017.
Etrasimod Pyoderma gangrenosum (PG) Phase 2 Phase 2 trial initiated March 2017.
Etrasimod Dermatological extraintestinal manifestations (EIM) in patients with inflammatory bowel disease (IBD) Phase 2 Phase 2 trial initiated March 2017.
Etrasimod Ulcerative colitis Phase 2 Phase 2 data due 1Q 2018.
Lorcaserin Obesity Approved Approved June 27, 2012.
Lorcaserin Smoking cessation Phase 2 Phase 2 initiated March 2014. Data released Nov 2014
Ralinepag Pulmonary Arterial Hypertension Phase 2 Phase 2 data released July 10, 2017. Primary endpoint met. Secondary missed.
$1.76
+0.03  1.73%
$153.3 million
87.1 million
2.61
01/15/2018
Tap to view 3 drugs
Drug Indication Stage News
ARQ 092 Overgrowth Diseases Phase 1/2 Phase 1/2 trial has commenced enrollment - May 4, 2017.
Derazantinib (ARQ 087) intrahepatic cholangiocarcinoma (iCCA) Phase 3 Phase 2 data at ASCO June 3, 2017 - ORR 21%. Phase 3 trial to commenced enrollment 3Q 2017.
Tivantinib (ARQ 197) METIV-HCC trial Previously treated Inoperable Hepatocellular Carcinoma cancer Phase 3 Phase 3 top-line data released February 17, 2017 - primary endpoint not met.
$15.56
+2.42  18.42%
$3.1 billion
197 million
4.83
01/19/2018
Tap to view 7 drugs
Drug Indication Stage News
ARRY 797 LMNA A/C-related dilated cardiomyopathy (DCM) Phase 2 Phase 2 data presented at the European Society of Cardiology on August 30, 2016. Phase 3 trial planned.
ARRY-382 and Keytruda Non-small cell lung cancer Phase 1/2 Phase 1/2 initial efficacy data presented in poster November 10, 2017 at SITC.
Binimetinib - COLUMBUS BRAF mutant melanoma cancer PDUFA Phase 3 data released September 26, 2016 met primary endpoint. PDUFA date June 30, 2018 - no Adcom anticipated.
Binimetinib - MILO Recurrent low-grade serous ovarian cancer (LGSOC) Phase 3 Phase 3 trial discontinued April 2016
Binimetinib (NEMO) NRAS melanoma - cancer Phase 3 PDUFA date originally set for June 30, 2017. Announed withdrawl of NDA filing - March 20, 2017.
Encorafenib and cetuximab - BEACON CRC BRAF-Mutant Colorectal Cancer Phase 3 Data at ESMO September 2017. ORR 41%. Median duration of treatment was 5.6 months. Updated data due at ASCO GI January 20, 2018.
Selumetinib - SELECT-1 Differentiated thyroid cancer Phase 3 Phase 3 trial did not meet its primary endpoint - August 2016
$6.39
+0.10  1.59%
$478.2 million
74.8 million
2.33
11/30/2016
Tap to view 3 drugs
Drug Indication Stage News
ARC-520 injection in combination with entecavir or tenofovir Chronic Hepititis B (HBV) Phase 2 Announced that development will be discontinued - November 29, 2016.
ARC-521 Chronic Hepititis B (HBV) Phase 1/2 Announced that development will be discontinued - November 29, 2016.
ARC-AAT Alpha-1 antitrypsin deficiency (AATD) Phase 2 Announced that development will be discontinued - November 29, 2016.
$47.48
+1.23  2.66%
$826 million
17.4 million
2.07
07/25/2016
Tap to view 1 drug
Drug Indication Stage News
VEN 307 (diltiazem cream) Anal fissures Phase 3 Phase 3 data from second trial did not meet primary endpoint - Feb 2014. Will not pursue future development
$53.69
+2.16  4.19%
$2 billion
36.4 million
3.04
01/04/2018
Tap to view 1 drug
Drug Indication Stage News
TransCon Growth hormone deficiency in children Phase 3 Phase 3 completion of enrollment announced January 3, 2018. Data due 1Q 2019.
$13.98
+0.35  2.57%
$191.4 million
13.7 million
1.05
01/17/2018
Tap to view 1 drug
Drug Indication Stage News
ASN100 Staphylococcus aureus Phase 2 Phase 2 top-line data due 2H 2018. Power analysis due 1H 2018.
$1.93
+0.01  0.52%
$228.8 million
118.5 million
14.57
01/15/2018
Tap to view 3 drugs
Drug Indication Stage News
Multistem Ischemic stroke Phase 3 Phase 2 data released mid April 2015. Endpoints not met. Phase 3 MASTERS-2 trial planned.
Multistem Acute myocardial infarction Phase 2 Phase 2 enrolment but reported May 2016 that enrolment is slower than expected
Multistem - TREASURE (Japan) Ischemic stroke Phase 2/3 Phase 2/3 enrollment commenced November 2017 (Japan).
$0.74
-0.00  -0.54%
$58.8 million
80 million
2.35
01/15/2018
Tap to view 3 drugs
Drug Indication Stage News
Actimab-A Acute Myeloid Leukemia (AML) Phase 2 Phase 2 to initiated September 2016. Poster at ASH December 10, 2017 showed 69% ORR with top-line data due 1H 2018.
Actimab-MDS Myelodysplastic syndrome (MDS) Phase 1/2 Phase 1/2 trial to be initiated 2018.
Iomab-B Hematopoietic Stem Cells Transplantation Phase 3 Phase 3 initiated June 2016. Enrollment to be completed by the end of 2018. Data due 2H 2019.
$16.34
-0.99  -5.71%
$947.6 million
58 million
5.13
01/22/2018
Tap to view 4 drugs
Drug Indication Stage News
KX-01 Ointment Actinic keratosis Phase 3 Phase 3 patient recruitment announced September 25, 2017.
Oraxol Breast cancer Phase 1 Phase 1 preliminary data showed 50% PR and 50% SD among first 12 patients.
Oraxol Metastatic breast cancer Phase 3 Phase 3 second interim analysis due mid-2018.
Oraxol and CYRAMZA (Ramucirumab) Phase 1b Phase 1b data showed PR 2/6, SD 3/6.
$0.34
+0.01  4.12%
$10.8 million
31.8 million
1.03
01/15/2018
Tap to view 3 drugs
Drug Indication Stage News
Endoxifen Breast cancer - patients who are not responding to Tamoxifen Phase 2 Phase 2 trial to be initiated 1Q 2018. Trial to be completed 2018.
Endoxifen Mammographic breast density (MBD) Phase 2 Phase 2 trial to be initiated 1Q 2018. Trial to be completed 2018.
Fulvestrant Cuctal carcinoma in situ(DCIS) - invasive breast cancer Phase 2 Phase 2 trial ongoing - noted December 28, 2017.
$33.35
+3.85  13.05%
$1 billion
30.6 million
9.40
01/15/2018
Tap to view 5 drugs
Drug Indication Stage News
ATA 129 - ALLELE Epstein-Barr virus (EBV-PTLD) after solid organ transplant (SOT) Phase 3 Phase 3 trial initiation announced January 3, 2017. Data due 1H 2019.
ATA 129 - MATCH Epstein-Barr virus (EBV-PTLD) after after hematopoietic cell transplant (HCT) Phase 3 Phase 3 trial initiation announced January 3, 2017.
ATA129 and KEYTRUDA Nasopharyngeal carcinoma (NPC) Phase 1/2 Phase 1/2 trial to be initiated 2018.
ATA188 Multiple sclerosis Phase 1 Received clearance to initiate enrollment at US sites - January 10, 2018. Data due 1H 2019.
PINTA 745 Protein-energy wasting Phase 2 Phase 2 endpoint not met December 2015
$2.25
+0.00  0.00%
$352.5 million
156.7 million
2.99
01/16/2018
Tap to view 4 drugs
$5.80
+0.23  4.13%
$487.5 million
84.1 million
9.21
11/15/2017
Tap to view 4 drugs
$11.22
+0.23  2.09%
$446.1 million
39.8 million
1.84
01/12/2018
Tap to view 5 drugs
Drug Indication Stage News
Akovaz Hypotension Approved Announced approval May 2 2016
Bloxiverz (neostigmine methylsulfate) Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery Approved Approved June 3, 2013.
Bloxiverz (neostigmine methylsulfate) Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery Approved Approved Jun 3 2013
Micropump Sodium Oxybate Excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy Phase 3 Phase 3 SPA agreed on - October 2016. Initiation of dosing announced December 16, 2016.
VAZCULEP (phenylephrine hydrochloride) Clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia Approved Approved June 30 2014.
$2.97
+0.04  1.37%
$351.4 million
118.3 million
4.70
01/15/2018
Tap to view 4 drugs
Drug Indication Stage News
Ficlatuzumab EGFR-mutated Non-small cell lung cancer (NSCLC) Phase 2 Announced September 12, 2016 that its Phase 2 trial has been discontinued
Ficlatuzumab and cetuximab Head and neck squamous cell carcinoma (HNSCC) Phase 2 Phase 2 initiation announced December 7, 2017.
TIVO-3 - tivozanib Third line treatment of patients with renal cell cancer Phase 3 Phase 3 completion of enrollment noted June 20, 2017. Futility analysis released October 6, 2017 - trial to continue as planned. Top-line data due 2Q 2018.
Tivozanib + Opdivo Renal cell cancer (RCC) Phase 1/2 Enrollment of Phase 2 portion of Phase 1/2 trial complete with initial Phase 2 data due at Genitourinary Cancers Symposium February 8-10, 2018.
$0.62
-0.05  -8.15%
$23.8 million
38.6 million
1.49
11/29/2017
Tap to view 4 drugs
Drug Indication Stage News
BTA074 5% topical gel Condyloma Phase 2 Phase 2 completion of enrollment announced November 29, 2017 with data due 2Q 2018.
BTA585 Respiratory syncytial virus (RSV) Phase 2a Phase 2a data released February 1, 2017 - primary endpoint not met.
Laninamivir Octanoate - IGLOO Adults with symptomatic influenza A or B infection Phase 2 Phase 2 initiated Jun 2013. Topline data did not meet the primary endpoint - July 2014
Vapendavir - SPIRITUS trial Human rhinovirus (HRV) Phase 2b Phase 2b top-line data released February 13, 2017 - primary endpoint not met.
$3.03
+0.02  0.66%